An immunological method for the detection of BCR-ABL fusion protein and monitoring its activation
- 30 June 2008
- journal article
- Published by Elsevier in Leukemia Research
- Vol. 32 (6) , 936-943
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- The development of imatinib as a therapeutic agent for chronic myeloid leukemiaBlood, 2005
- AMN107: Tightening the grip of imatinibCancer Cell, 2005
- Free circulating soluble CD52 as a tumor marker in chronic lymphocytic leukemia and its implication in therapy with anti‐CD52 antibodiesCancer, 2004
- Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistanceLeukemia, 2004
- Phosphatidylinositol‐3 kinase inhibitors reproduce the selective antiproliferative effects of imatinib on chronic myeloid leukaemia progenitor cellsBritish Journal of Haematology, 2004
- Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon α/ara-CLeukemia, 2003
- Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid LeukemiaNew England Journal of Medicine, 2003
- Profiling of tyrosine phosphorylation pathways in human cells using mass spectrometryProceedings of the National Academy of Sciences, 2003
- Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous LeukemiaNew England Journal of Medicine, 2002
- c-Abl Has High Intrinsic Tyrosine Kinase Activity That Is Stimulated by Mutation of the Src Homology 3 Domain and by Autophosphorylation at Two Distinct Regulatory TyrosinesJournal of Biological Chemistry, 2000